Tony Berberabe, MPH

Articles

New Biomarkers for Responses Are Explored in Late-Stage Ovarian Cancer

July 4th 2019

The identification of appropriate biomarkers for evaluating responses to therapy would be beneficial across all stages of ovarian cancer, from early to advanced.

Oncology Practices Can Preserve Independence With a Strong Marketing Effort

June 29th 2019

From 2016 to 2018, there was an 8% increase in the number of community oncology practices consolidated into hospital systems, and this trend has many independent practices struggling to avoid the same fate. Two winning strategies are emerging to help practices remain independent.

Early Findings Show Activity for Cytokine Agonist in BCG-Unresponsive Bladder Cancer

June 27th 2019

Use of a cytokine agonist in combination with BCG was highly successful in stimulating an immune response in previously BCG-unresponsive patients with carcinoma in situ high-grade nonmuscle invasive bladder cancer, according to early trial results presented by Sam S. Chang, MD, MBA, at the 2019 American Urological Association Annual Meeting.

Enzalutamide Improves rPFS Regardless of PSA Levels in Hormone-Sensitive Prostate Cancer

June 25th 2019

Enzalutamide in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer demonstrated significantly improved radiographic progression-free survival versus placebo plus ADT, regardless of baseline prostate-specific antigen levels, according to expanded findings from the ARCHES study.

Fee-for-Service Unlikely to Disappear Soon

April 15th 2019

Fee-for-service tends to result in a surplus of care and unnecessary medical expense, but it probably won’t disappear from the landscape soon.

Reminder App With Postsurgery Instructions Well Received by Patients With Ovarian Cancer

January 12th 2019

Nearly 1 IN 5 women who undergoes ovarian cancer surgery is readmitted for complications, but a web-based app may improve patient monitoring so complications and adverse events can be addressed quickly by the patient’s care team.

Prostate Cancer Mortality Progress Stalls, Prompting Questions About PSA Policies

January 9th 2019

An analysis of prostate cancer trends adjusted for delays in reporting by stage of disease showed that incidence of late-stage disease increased from 2010 to 2014 after a decline in prostate-specific antigen use.

Should Fitness Trackers Be Used to Assess Performance Status in Patients With Cancer?

September 23rd 2018

Using wearable activity monitors may eventually supplement standard assessments of performance status and functionality that could inform clinicians, especially because objective evaluation of performance status is difficult to determine.

Steady Increase in Liver Cancer Death Rates Observed in Adults Aged 25 and Older

September 22nd 2018

A National Center for Health Statistics briefing showed that liver cancer death rates increased significantly for both sexes, with death rates for men 2 to 2.5 times the rate for women from 2000 through 2016.

Wolmark's Passion for Evidence-Based Medicine Helped Transform Cancer Care

July 30th 2018

Norman Wolmark, MD, a 2017 Giants of Cancer Care® award winner in the Breast Cancer category, played a pivotal role in building the clinical trials program at the National Surgical Adjuvant Breast and Bowel Project.

SGO Survey: Higher Levels of Resilience and Flourishing Correlate With Lower Burnout

July 7th 2018

Symptoms of burnout continue to plague the physician community overall, but a recent survey suggests that factors such as resiliency and the ability to flourish can diminish its detrimental effects.

Findings Set Stage for Expanded Immunotherapy Role in Bladder Cancer

June 26th 2018

Researchers now are turning their attention toward earlier disease settings involving patients who are refractory to standard therapies in nonmuscle-invasive bladder cancer or who are poor candidates for surgery in muscle-invasive bladder cancer.

Patients Aged

June 13th 2018

Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.

Lynch's Career Brings Clinic and Laboratory Advancements Into Focus

April 3rd 2018

Thomas J. Lynch, Jr, MD, brings an enthusiasm to exploring and developing treatments to help patients with cancer.

Molecular Subtypes Correlate With Outcomes in RCC

January 16th 2018

Molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with significant differences seen in overall survival and disease-free survival between groupings.

With the Aid of an Upgraded Acuity Tool, Fewer Patients Slip Through the Cracks

December 23rd 2017

A caseload management tool developed at the Mitchell Cancer Institute at the University of South Alabama offers a comprehensive portrait of a patient's condition that helps oncology nurse navigators to allocate their time and resources efficiently and enables managers to optimize patient care by assigning appropriate caseloads.

Molecular Subtypes Prognostic for OS, DFS in Clear-Cell RCC

November 18th 2017

Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.

Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC

November 18th 2017

An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.

Refining Role of Brentuximab Vedotin and Immunotherapy in Hodgkin Lymphoma

November 9th 2017

As clinicians’ understanding of the disease pathobiology associated with Hodgkin lymphoma (HL) has increased, novel treatments have emerged.

Innovators Lauded With Giants Awards

June 2nd 2017

Twelve creative and influential oncology research leaders are the winners of the 2017 Giants of Cancer Care® awards, a unique honor that recognizes physician-scientists who have helped move cancer care forward.